XML 46 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Shareholders' Equity (Tables)
6 Months Ended
Sep. 30, 2024
Shareholders' Equity [Abstract]  
Derivative Warrant Liabilities Measured at Fair Value and Reconciliation of Changes in Fair Value
The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following table:

   
September 30,
2024
   
September 30,
2023
 
   
$    
$  
Beginning balance
   
4,359
     
 
Issued during the period
   
     
1,631
 
Change in fair value
   
(1,756
)
   
1,826
 
Ending balance
   
2,603
     
3,457
 
Fair Value Assumptions
The fair value of derivative warrant liabilities were determined based on the fair value of the Common Warrants at the issue date and the reporting dates using the Black-Scholes model with the following weighted-average assumptions that will expire on the earlier of (i) the 60th day after the date of the acceptance by the FDA of an NDA for the Company’s product candidate GTx-104 or (ii) five years from the date on issuance.

   
September 30,
2024
   
March 31,
2024
 
Risk-free interest rate
   
3.90
%
   
4.69
%
Share price
 
$
3.00
   
$
3.43
 
Expected warrant life
   
1.59
     
2.03
 
Dividend yield
   
0
%
   
0
%
Expected volatility
   
69.14
%
   
85.94
%